D I Laboratories Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 26-06-2024
- Paid Up Capital ₹ 0.80 M
as on 26-06-2024
- Company Age 38 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 2.80 M
as on 26-06-2024
- Revenue %
(FY 2020)
- Profit -29.33%
(FY 2020)
- Ebitda -31.01%
(FY 2020)
- Net Worth -2.87%
(FY 2020)
- Total Assets -6.17%
(FY 2020)
About D I Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 0.80 M.
The company has closed loans amounting to ₹2.80 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Swarup Chakraborty, Biman Saha, and Sandip Ghosh serve as directors at the Company.
- CIN/LLPIN
U24239WB1986PLC041034
- Company No.
041034
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
31 Jul 1986
- Date of AGM
30 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at D I Laboratories?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Swarup Chakraborty  | Director | 25-Nov-2022 | Current |
| Biman Saha | Director | 25-Nov-2002 | Current |
| Sandip Ghosh | Director | 10-Feb-1988 | Current |
Financial Performance and Corporate Structure Insights of D I Laboratories.
D I Laboratories Ltd, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 29.33% decrease in profit. The company's net worth dipped by a decrease of 2.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of D I Laboratories?
In 2019, D I Laboratories had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
_PRIVATE_LIMITED.webp)
Dcg Data-Core Systems (India) Private LimitedActive 9 years 4 monthsSwarup Chakraborty is a mutual person
Bengal Dcl Housing Development Company LimitedActive 25 years 8 monthsSwarup Chakraborty is a mutual person
Healthtek India Private LimitedActive 2 years 5 monthsSwarup Chakraborty and Sandip Ghosh are mutual person
_PRIVATE_LIMITED.webp)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Uco Bank Creation Date: 14 Dec 1987 | ₹2.80 M | Satisfied |
How Many Employees Work at D I Laboratories?
D I Laboratories has a workforce of 28 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of D I Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped D I Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
